Ameritas Advisory Services’s Galectin Therapeutics GALT Stock Holding History

Ameritas Advisory Services’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-44,232	Closed	-$64.6K	–	816
2023 Q2	$64.6K	Sell	44,232 -1,070	-2%	-$1.81K	0.01%	539
2023 Q1	$94.9K	Hold	45,302	–	–	﹤0.01%	1023
2022 Q4	$51.2K	Hold	45,302	–	–	﹤0.01%	863
2022 Q3	$74K	Hold	45,302	–	–	﹤0.01%	742
2022 Q2	$59K	Buy	45,302 +1,070	+2%	+$1.54K	﹤0.01%	784
2022 Q1	$71K	Hold	44,232	–	–	﹤0.01%	818
2021 Q4	$92K	Buy	+44,232	New	+$126K	﹤0.01%	798

Other funds holding GALT

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return

AWS

Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Ameritas Advisory Services's GALT Position: Q3 2023 in Review

Ameritas Advisory Services sold out of Galectin Therapeutics (GALT) in Q3 2023, closing a stake of 44,232 shares — an estimated $64.6K sold.

Ameritas Advisory Services first reported a position in GALT in Q4 2021 and held it in 7 quarters. The position peaked at $94.9K in Q1 2023. 60 funds tracked by Wall St. Rank hold GALT as of Q3 2023.

Ameritas Advisory Services reported no remaining Galectin Therapeutics position as of Q3 2023 after selling out during the quarter.
Ameritas Advisory Services sold 44,232 Galectin Therapeutics shares in Q3 2023, an estimated $64.6K.
Ameritas Advisory Services first reported a position in Galectin Therapeutics in Q4 2021 and held it in 7 quarters.
Ameritas Advisory Services's Galectin Therapeutics position peaked at $94.9K in Q1 2023.
60 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2023.

Based on Ameritas Advisory Services's 13F filing for Q3 2023, filed 13 Nov 2023.